Dr Schroeder holds a MSc. in Chemistry from University of Kalmar, Sweden, a Ph.D. in Pharmacology from the University of Queensland, Australia, and a Graduate Certificate in Research Management from Southern Cross University, Australia. She has carried out postdoctoral training at The Scripps Research Institute, USA, the University of Queensland, and the University of New South Wales, Australia. She started her independent career in 2014 at the University of Queensland’s Institute for Molecular Bioscience focusing her research on biodiscovery and peptide engineering of venom-derived bioactive peptides for the development of novel peptide-based drug leads for diseases including pain and cancer and was promoted to Associate Professor in 2020. In 2020 she moved her research to the National Cancer Institute’s Chemical Biology Laboratory, Frederick, MD, taking up a position as a Stadtman Fellow, keeping her ties with the University of Queensland as an adjunct Associate Professor position. In 2022 she joined the Peptide Therapeutics department at Genentech as a Senior Fellow where she leads the disulfide-constrained peptide discovery platform.